CYTARABINE EG 50 mg/ml, solution for injection bottle, 20 ml
Active ingredients: Cytarabine
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 20 mlintrathécale;intraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CYTARABINE EG 50 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intrathécale;intraveineuse;sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 20 ml
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Jun 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60369984CIP75700713CIP133400957007133Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CYTARABINEsolution | 50 mg · 1 ml de solution injectable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.